专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100216815A1 N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS 失效
公开(公告)号：US20100216815A1
公开(公告)日：2010-08-26
申请号：US12678357
申请日：2008-09-30
申请人： Joseph L. Duffy , Scott B. Hoyt , Clare London
发明人： Joseph L. Duffy , Scott B. Hoyt , Clare London
IPC分类号： A61K31/497 , C07D403/14 , A61K31/506 , C07D239/42 , C07D401/04 , A61K31/4439 , C07D241/20 , C07D403/04 , A61K31/4178 , C07D249/14 , A61K31/427 , A61P29/00 , A61P25/08
CPC分类号： C07D403/14 , C07D401/04 , C07D401/14 , C07D403/04
摘要： A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

2. 发明申请

US20100204247A1 N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS 审中-公开
标题翻译： N-取代的氧化硅衍生物作为钙通道阻断剂
公开(公告)号：US20100204247A1
公开(公告)日：2010-08-12
申请号：US12678820
申请日：2008-09-30
申请人： Joseph L. Duffy , Scott B. Hoyt , Clare London , Christian P. Stevenson
发明人： Joseph L. Duffy , Scott B. Hoyt , Clare London , Christian P. Stevenson
IPC分类号： A61K31/506 , A61K31/4439 , A61P25/08 , A61K31/4196
CPC分类号： A61K31/405
摘要： A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
摘要翻译：一系列由式I表示的N-取代的羟基吲哚衍生物或其药学上可接受的盐。药物组合物包含单独的或与一种或多种其它治疗活性化合物组合的有效量的本发明化合物和药学上可接受的载体。治疗与钙通道活性相关或由其引起的疾病的方法，包括例如急性疼痛，慢性疼痛，内脏痛，炎性疼痛，神经性疼痛，尿失禁，瘙痒，过敏性皮炎，癫痫，糖尿病性神经病，肠易激综合征综合征，抑郁症，焦虑症，多发性硬化症，睡眠障碍，双相性精神障碍和中风，包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物组合施用。

3. 发明授权

US08273749B2 N-substituted oxindoline derivatives as calcium channel blockers 失效
标题翻译： N-取代的羟基吲哚衍生物作为钙通道阻断剂
公开(公告)号：US08273749B2
公开(公告)日：2012-09-25
申请号：US12678357
申请日：2008-09-30
申请人： Joseph L. Duffy , Scott B. Hoyt , Clare London
发明人： Joseph L. Duffy , Scott B. Hoyt , Clare London
IPC分类号： A61K31/4015 , C07D209/34 , C07D241/14 , C07D401/04
CPC分类号： C07D403/14 , C07D401/04 , C07D401/14 , C07D403/04
摘要： A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
摘要翻译：一系列由式I表示的N-取代的羟基吲哚衍生物或其药学上可接受的盐。药物组合物包含单独的或与一种或多种其它治疗活性化合物组合的有效量的本发明化合物和药学上可接受的载体。治疗与钙通道活性相关或由其引起的疾病的方法，包括例如急性疼痛，慢性疼痛，内脏痛，炎性疼痛，神经性疼痛，尿失禁，瘙痒，过敏性皮炎，癫痫，糖尿病性神经病，肠易激综合征综合征，抑郁症，焦虑症，多发性硬化症，睡眠障碍，双相性精神障碍和中风，包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物组合施用。

4. 发明申请

US20110136842A1 Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers 审中-公开
标题翻译：取代的二氢异喹啉酮和异喹啉二酮衍生物作为钙通道阻断剂
公开(公告)号：US20110136842A1
公开(公告)日：2011-06-09
申请号：US13057326
申请日：2009-07-27
申请人： Joseph L. Duffy , Scott B. Hoyt , Clare London , Christian P. Stevenson , Andres M. Ullman
发明人： Joseph L. Duffy , Scott B. Hoyt , Clare London , Christian P. Stevenson , Andres M. Ullman
IPC分类号： A61K31/47 , C07D217/24 , C07D401/04 , C07D401/06 , C07D401/14 , A61K31/506 , A61P29/00 , A61P25/00 , A61P25/08
CPC分类号： C07D217/24
摘要： A series of disubstituted dihydroisoquinolinone and isoquinolinedione derivatives represented by Formula I, or pharmaceutically acceptable salts thereof are presented. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
摘要翻译：提供了一系列由式I表示的二取代二氢异喹啉酮和异喹啉二酮衍生物或其药学上可接受的盐。药物组合物包含单独的或与一种或多种其它治疗活性化合物组合的有效量的本发明化合物和药学上可接受的载体。治疗与钙通道活性相关或由其引起的疾病的方法，包括例如急性疼痛，慢性疼痛，内脏痛，炎性疼痛，神经性疼痛，尿失禁，瘙痒，过敏性皮炎，癫痫，糖尿病性神经病，肠易激综合征综合征，抑郁症，焦虑症，多发性硬化症，睡眠障碍，双相性精神障碍和中风，包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物组合施用。

5. 发明授权

US07888345B2 Benzaepinones as sodium channel blockers 失效
标题翻译： Benzaepinones作为钠通道阻滞剂
公开(公告)号：US07888345B2
公开(公告)日：2011-02-15
申请号：US12308209
申请日：2007-06-05
申请人： Scott B. Hoyt , Clare London , Dong Ok , William H. Parsons
发明人： Scott B. Hoyt , Clare London , Dong Ok , William H. Parsons
IPC分类号： C07D223/16 , A61K31/55 , A61P29/02
CPC分类号： C07D223/16 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12
摘要： Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.
摘要翻译：由式（I）表示的苯并氮杂酮化合物或其药学上可接受的盐。药物组合物包含单独的或与一种或多种其它治疗活性化合物组合的有效量的本发明化合物和药学上可接受的载体。治疗与钠通道活性相关或由其引起的症状的方法，包括例如急性疼痛，慢性疼痛，内脏痛，炎性疼痛，神经性疼痛，癫痫，肠易激综合征，尿失禁，瘙痒，瘙痒，过敏性皮炎抑郁，焦虑，多发性硬化和双相性精神障碍，包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物组合施用。施用局部麻醉的方法包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物和药学上可接受的载体组合施用。

6. 发明授权

US09073929B2 Aldosterone synthase inhibitors 有权
标题翻译：醛固酮合酶抑制剂
公开(公告)号：US09073929B2
公开(公告)日：2015-07-07
申请号：US14112945
申请日：2012-04-20
申请人： Scott B. Hoyt , Whitney Lane Petrilli , Clare London , Yusheng Xiong , Jerry Andrew Taylor , Amjad Ali , Michael Man-Chu Lo , Timothy J. Henderson , Qingzhong Hu , Rolf Hartmann , Lina Yin , Ralf Heim , Emmanuel Bey , Rohit Saxena , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
发明人： Scott B. Hoyt , Whitney Lane Petrilli , Clare London , Yusheng Xiong , Jerry Andrew Taylor , Amjad Ali , Michael Man-Chu Lo , Timothy J. Henderson , Qingzhong Hu , Rolf Hartmann , Lina Yin , Ralf Heim , Emmanuel Bey , Rohit Saxena , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
IPC分类号： C07D471/04 , C07D487/04 , C07D519/00 , A61K31/41 , A61K45/06
CPC分类号： C07D487/04 , A61K31/41 , A61K45/06 , C07D471/04 , C07D519/00 , A61K2300/00
摘要： This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
摘要翻译：本发明涉及式I的三环三唑类似物或其药学上可接受的盐，其中该变量在本文中定义。本发明化合物选择性地抑制醛固酮合成酶。本发明还提供包含式I化合物或其盐的药物组合物，以及用于治疗，改善或预防可通过抑制醛固酮合成酶治疗的病症的方法。

7. 发明申请

US20140045819A1 ALDOSTERONE SYNTHASE INHIBITORS 有权
公开(公告)号：US20140045819A1
公开(公告)日：2014-02-13
申请号：US14112945
申请日：2012-04-20
申请人： Scott B. Hoyt , Whitney Lane Petrilli , Clare London , Yusheng Xiong , Jerry Andrew Taylor , Amjad Ali , Michael Man-Chu Lo , Timothy J. Henderson , Qingzhong Hu , Rolf Hartmann , Lina Yin , Ralf Heim , Emmanuel Bey , Rohit Saxena , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
发明人： Scott B. Hoyt , Whitney Lane Petrilli , Clare London , Yusheng Xiong , Jerry Andrew Taylor , Amjad Ali , Michael Man-Chu Lo , Timothy J. Henderson , Qingzhong Hu , Rolf Hartmann , Lina Yin , Ralf Heim , Emmanuel Bey , Rohit Saxena , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , A61K31/41 , A61K45/06 , C07D471/04 , C07D519/00 , A61K2300/00
摘要： This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
摘要翻译：本发明涉及式I的三环三唑类似物或其药学上可接受的盐，其中该变量在本文中定义。本发明化合物选择性地抑制醛固酮合成酶。本发明还提供包含式I化合物或其盐的药物组合物，以及用于治疗，改善或预防可通过抑制醛固酮合成酶治疗的病症的方法。

8. 发明申请

US20130317057A1 ALDOSTERONE SYNTHASE INHIBITORS 有权
公开(公告)号：US20130317057A1
公开(公告)日：2013-11-28
申请号：US13811059
申请日：2011-07-20
申请人： Scott B. Hoyt , Min K. Park , Clare London , Yusheng Xiong , D. Jonathan Bennett , Jaiqiang Cai , Paul Ratcliffe , Andrew Cooke , Emma Carswell , John MacLean , Rohit Saxena , Bheemashankar A. Kulkarni , Archana Gupta
发明人： Scott B. Hoyt , Min K. Park , Clare London , Yusheng Xiong , D. Jonathan Bennett , Jaiqiang Cai , Paul Ratcliffe , Andrew Cooke , Emma Carswell , John MacLean , Rohit Saxena , Bheemashankar A. Kulkarni , Archana Gupta
IPC分类号： C07D401/04 , C07D413/14 , A61K31/4375 , A61K31/4709 , A61K31/4439 , C07D471/04
CPC分类号： C07D401/04 , A61K31/4184 , A61K31/4375 , A61K31/4439 , A61K31/4709 , C07D413/14 , C07D471/04
摘要： The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.
摘要翻译：本发明涉及结构式（I）的化合物及其药学上可接受的盐。本发明的化合物对选择性抑制CYP11B2有效，因此可用于治疗或预防与升高的醛固酮水平相关的病症，包括但不限于高血压和心力衰竭。

9. 发明授权

US09351973B2 Pyrazolopyridyl compounds as aldosterone synthase inhibitors 有权
标题翻译：吡唑并吡啶基化合物作为醛固酮合酶抑制剂
公开(公告)号：US09351973B2
公开(公告)日：2016-05-31
申请号：US14346518
申请日：2012-09-17
申请人： D. Jonathan Bennett , Jaiqiang Cai , Emma Carswell , Andrew Cooke , Scott B. Hoyt , Clare London , John MacLean , Min K. Park , Paul Ratcliffe , Yusheng Xiong , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
发明人： D. Jonathan Bennett , Jaiqiang Cai , Emma Carswell , Andrew Cooke , Scott B. Hoyt , Clare London , John MacLean , Min K. Park , Paul Ratcliffe , Yusheng Xiong , Swapan Kumar Samanta , Bheemashankar A. Kulkarni
IPC分类号： C07D471/04 , A61K31/437 , C07D487/04 , A61K31/519 , A61P9/12 , A61P13/12 , A61P9/00 , A61P9/10 , A61P1/16
CPC分类号： A61K31/519 , A61K31/437 , A61K31/444 , C07D471/04 , C07D487/04
摘要： This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
摘要翻译：本发明涉及以下结构式的吡唑并吡啶基化合物或其药学上可接受的盐，其中该变量在本文中定义。本发明化合物选择性地抑制醛固酮合酶。本发明还提供包含式I化合物或其盐的药物组合物，以及潜在的治疗，改善或预防可通过抑制醛固酮合酶治疗的病症的方法。

10. 发明授权

US09173873B2 Imidazopyridyl compounds as aldosterone synthase inhibitors 有权
公开(公告)号：US09173873B2
公开(公告)日：2015-11-03
申请号：US14346403
申请日：2012-09-17
申请人： Amjad Ali , D. Jonathan Bennett , Jaiqiang Cai , Emma Carswell , Andrew Cooke , Scott B. Hoyt , Michael Lo , Clare London , John MacLean , Min K. Park , Paul Ratcliffe , Jerry Andrew Taylor , Brent Whitehead , Yusheng Xiong
发明人： Amjad Ali , D. Jonathan Bennett , Jaiqiang Cai , Emma Carswell , Andrew Cooke , Scott B. Hoyt , Michael Lo , Clare London , John MacLean , Min K. Park , Paul Ratcliffe , Jerry Andrew Taylor , Brent Whitehead , Yusheng Xiong
IPC分类号： A61K31/437 , C07D471/04 , C07D487/04
摘要： This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式